613 related articles for article (PubMed ID: 22482453)
21. [The proceeding of drug development based on the propagation of tau protein].
Suzuki G; Hasegawa M
Nihon Rinsho; 2016 Mar; 74(3):432-7. PubMed ID: 27025082
[TBL] [Abstract][Full Text] [Related]
22. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
Chen F; David D; Ferrari A; Götz J
Curr Drug Targets; 2004 Aug; 5(6):503-15. PubMed ID: 15270197
[TBL] [Abstract][Full Text] [Related]
23. Tauopathies.
Hernández F; Avila J
Cell Mol Life Sci; 2007 Sep; 64(17):2219-33. PubMed ID: 17604998
[TBL] [Abstract][Full Text] [Related]
24. Altered Proteostasis in Neurodegenerative Tauopathies.
Papanikolopoulou K; Skoulakis EMC
Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
[TBL] [Abstract][Full Text] [Related]
25. Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy.
Espíndola SL; Damianich A; Alvarez RJ; Sartor M; Belforte JE; Ferrario JE; Gallo JM; Avale ME
Cell Rep; 2018 Apr; 23(3):709-715. PubMed ID: 29669277
[TBL] [Abstract][Full Text] [Related]
26. Differential interaction and aggregation of 3-repeat and 4-repeat tau isoforms with 14-3-3zeta protein.
Sadik G; Tanaka T; Kato K; Yanagi K; Kudo T; Takeda M
Biochem Biophys Res Commun; 2009 May; 383(1):37-41. PubMed ID: 19324008
[TBL] [Abstract][Full Text] [Related]
27. Tau isoform-specific stabilization of intermediate states during microtubule assembly and disassembly.
Best RL; LaPointe NE; Liang J; Ruan K; Shade MF; Wilson L; Feinstein SC
J Biol Chem; 2019 Aug; 294(33):12265-12280. PubMed ID: 31266806
[TBL] [Abstract][Full Text] [Related]
28. Different tau species lead to heterogeneous tau pathology propagation and misfolding.
Dujardin S; Bégard S; Caillierez R; Lachaud C; Carrier S; Lieger S; Gonzalez JA; Deramecourt V; Déglon N; Maurage CA; Frosch MP; Hyman BT; Colin M; Buée L
Acta Neuropathol Commun; 2018 Nov; 6(1):132. PubMed ID: 30497516
[TBL] [Abstract][Full Text] [Related]
29. Co-Expression of Three Wild-Type 3R-Tau Isoforms Induces Memory Deficit via Oxidation-Related DNA Damage and Cell Death: A Promising Model for Tauopathies.
Xu C; Guo J; Li L; Wang X; Zhou Q; Sun D; Zhang S; Li S; Ye J; Liu Y; Liu E; Zeng P; Wang X; Yang Y; Wang JZ
J Alzheimers Dis; 2020; 73(3):1105-1123. PubMed ID: 31884489
[TBL] [Abstract][Full Text] [Related]
30. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.
Combs B; Voss K; Gamblin TC
Biochemistry; 2011 Nov; 50(44):9446-56. PubMed ID: 21942206
[TBL] [Abstract][Full Text] [Related]
31. Tau isoform composition influences rate and extent of filament formation.
Zhong Q; Congdon EE; Nagaraja HN; Kuret J
J Biol Chem; 2012 Jun; 287(24):20711-9. PubMed ID: 22539343
[TBL] [Abstract][Full Text] [Related]
32. Tau Toxicity in Neurodegeneration.
Liang SY; Wang ZT; Tan L; Yu JT
Mol Neurobiol; 2022 Jun; 59(6):3617-3634. PubMed ID: 35359226
[TBL] [Abstract][Full Text] [Related]
33. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
[TBL] [Abstract][Full Text] [Related]
34. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.
Falzone TL; Gunawardena S; McCleary D; Reis GF; Goldstein LS
Hum Mol Genet; 2010 Nov; 19(22):4399-408. PubMed ID: 20817925
[TBL] [Abstract][Full Text] [Related]
35. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.
Karch CM; Jeng AT; Goate AM
J Biol Chem; 2012 Dec; 287(51):42751-62. PubMed ID: 23105105
[TBL] [Abstract][Full Text] [Related]
36. Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro.
Han D; Qureshi HY; Lu Y; Paudel HK
J Biol Chem; 2009 May; 284(20):13422-13433. PubMed ID: 19304664
[TBL] [Abstract][Full Text] [Related]
37. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.
Josephs KA
Mayo Clin Proc; 2017 Aug; 92(8):1291-1303. PubMed ID: 28778262
[TBL] [Abstract][Full Text] [Related]
38. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies.
Ferreira A; Bigio EH
Mol Med; 2011; 17(7-8):676-85. PubMed ID: 21442128
[TBL] [Abstract][Full Text] [Related]
39. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
[TBL] [Abstract][Full Text] [Related]
40. Involvement of 14-3-3 in tubulin instability and impaired axon development is mediated by Tau.
Joo Y; Schumacher B; Landrieu I; Bartel M; Smet-Nocca C; Jang A; Choi HS; Jeon NL; Chang KA; Kim HS; Ottmann C; Suh YH
FASEB J; 2015 Oct; 29(10):4133-44. PubMed ID: 26103986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
